PT  - JOURNAL ARTICLE
AU  - Powers, Jenny
ED  - Mountzios, Giannis
TI  - Paclitaxel plus Bevacizumab is a Feasible Option for Chemoresistant SCLC
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 3
4099  - http://mdc.sagepub.com/content/14/3/9.short
4100  - http://mdc.sagepub.com/content/14/3/9.full
AB  - Salvage treatment combining paclitaxel and bevacizumab was feasible and improved outcomes in heavily pretreated patients with advanced, chemoresistant small cell lung cancer (SCLC) in a small single-center study conducted by the Hellenic Oncology Research Group. Safety concerns were an issue with these patients, who had poor prognoses and few treatment options.